Skip to content
Mario Balsa· @MarioBalsaMD · X·· 3 days agoScore70

HER2

Body · original

🔥 GI at #ESMO26 is bringing everything: organ preservation, immunotherapy, HER2, BRAF, RAS(ON), bispecifics…

@OncoAlert has already done the filtering and picked the must-watch GI studies from Madrid!

From AZUR skies to RAS(ON) roads 😉

@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara, @pashtoonkasi, @GillSharlene

758 views · 13 likes · 5 reposts · 0 replies

Conference abstracts
1766ROmatched by Rapid oral 1: Breast cancer, advanced stage

Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC

https://esmocongress.esmo.org
1780Pmatched by HER2+ breast cancer

Safety, social costs and quality of life (QOL) in HER2-positive (HER2+) breast cancer (BC) patients (pts) treated with pertuzumab + trastuzumab fixed-dose combination subcutaneous (PT FDC SC): The PERTURB study

https://esmocongress.esmo.org
1795TIPmatched by HER2+ breast cancer

A global, interventional, open-label trial of trastuzumab deruxtecan (T-DXd)–based therapy in first-line HER2-positive metastatic breast cancer: DESTINY-Breast Guide

https://esmocongress.esmo.org
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage

Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)

https://esmocongress.esmo.org
1844Pmatched by HR+ breast cancer

Gene-expression profiling of HR+/HER2- breast cancers arising in germline BRCA1/2 mutation carriers

https://esmocongress.esmo.org
引用@
🚨 #ESMO26 GI Cancer: Top Ten by @OncoAlert 🧬 From organ preservation in dMMR rectal and gastric cancer to RAS(ON) inhibition in pancreatic cancer and bispecifics in biliary tract cancer, our faculty picked the must-know GI abstracts from Madrid 👇 #GICancer #CRCSM @CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara , @pashtoonkasi , @GillSharlene
在 X 查看被引用的帖子

Source: Mario Balsa · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org